Evidence map›Paper›PMID 15531773›Full record

ReviewImmunologic research2004

T-cell activation in the curious world of the intestinal intraepithelial lymphocyte.

John R Klein

Abstract readReview
PubMed Publisher
In one paragraph

Review in Immunologic research, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Th17 cytokines and the gut mucosal barrier.Journal of clinical immunology · 2010
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

John R KleinDepartment of Diagnostic Sciences, Dental Branch, University of Texas Health Science Center at Houston, Houston, TX 77030, USA. john.r.klein@uth.tmc.edu

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In conventional terms, when T cells encounter appropriate stimuli, they are induced to undergo molecular and physical changes that confer upon them a state of activation. Once initiated, activation generally results in a state of full T-cell responsiveness in an all-or-none manner. Uniquely, however, the intestinal intraepithelial lymphocytes (IELs) bear features that are decidedly different from those of T cells located throughout other immunological compartments in that they exhibit some but not all properties of activated T cells, yet they can be induced to move further into activation provided appropriate costimulatory signals have been received. IEL costimulatory molecules some of which are constitutively expressed, whereas others are upregulated following T-cell receptor (TCR)/CD3 stimulation appear to hold the key to determining the nature and magnitude of the activational process. A system of activation such as this in the intestine would be expected to have great immunological protective value for the host because it would provide an untrammeled process of T-cell activation at a barrier site where the level of antigen exposure is consistently high. Clearly, however, mechanisms must be in place to insure that the IEL activation process is not inadvertently breached. These and other issues central to the operational workings of the intestinal immune system are elaborated in this article, and a model is presented in which IEL activation can be viewed as a layered, three-stage activational process.

Indexed as

AnimalsAntigens, CDAntigens, Differentiation, T-LymphocyteAntigens, LyCD3 ComplexCD69 AntigensEpithelial CellsHumansInducible T-Cell Co-Stimulator ProteinIntestinesLectins, C-TypeLeukosialinLymphocyte ActivationMiceModels, ImmunologicalReceptors, OX40Antigens, CDAntigens, Differentiation, T-LymphocyteAntigens, LyCD3 ComplexCD69 AntigensICOS protein, humanIcos protein, mouseInducible T-Cell Co-Stimulator ProteinLectins, C-TypeLeukosialinLy-6C antigen, mouseReceptors, OX40Receptors, Tumor Necrosis FactorSialoglycoproteinsSPN protein, humanSpn protein, mouseTNFRSF4 protein, humanTnfrsf4 protein, mouse

Identifiers

PMID15531773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.